Emmaus Life Sciences, Inc. · OTC:EMMA
Emmaus Life Sciences — MYnd Analytics — JP Morgan Healthcare Conference 2019
21 slides from Emmaus Life Sciences's conference presentation, Jan 7, 2019

Slide 1: Delivering Hope to Patients with Sickle Cell Disease
1 Delivering Hope to Patients with Sickle Cell Disease The First Treatment Developed Specifically for Sickle Cell Disease in almost 20 years January 2019 JP Morgan Healthcare Conference Filed by MYnd Analytics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to R

Slide 2: Important Information
2 2 Important Information IMPORTANT INFORMATION ABOUT THE TRANSACTIONS WILL BE FILED WITH THE SEC This communication is being made in respect of the proposed business combination involving MYnd Analytics, Inc. (“MYnd”) and Emm aus Life Sciences, Inc. (“Emmaus”). In connection with the proposed trans

Slide 3: Safe Harbor Statement
3 Safe Harbor Statement 3 This presentation contains forward - looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995 , regarding the research, development and potential commercialization of pharmaceutical products . Such forward - looking statements are b

Slide 4: A biopharmaceutical company with a plan for sustainable growth
4 We are a biopharmaceutical company with a plan for sustainable growth Initial thrust in sickle cell disease (SCD) Series of product platforms provides for growth across decades 4 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 SCD OUS Markets Diverticulosis SCD US Market

Slide 5: Investment Highlights
5 Investment Highlights □ Market Opportunity for treating Sickle Cell Disease (SCD) ▪ Underserved patient population and underdeveloped market – ripe for a new company – limited competition, no new treatments in ≈ 20 yrs. ▪ Orphan market (but large) – 100,000 patients in U.S. – significant revenue o

Slide 6: Sustainable Growth – Current and Pipeline
6 Sustainable Growth – Current and Pipeline 6 Endari for Sickle Cell Disease US 2018 --------------------------------- 2026 Xyndari for Sickle Cell Disease ROW 2020 --------------------------------------------------------- 2035 Xyndari for Sickle Cell Disease Europe 2020 ----------------------------

Slide 7: Financial Profile
7 Financial Profile ▪ Initial funding by NIH and FDA ▪ Raised over $125m in total ▪ SEC voluntary reporting company – nontrading ▪ Beneficial ownership – officers and directors ≈ 40% ▪ Strong initial sales ▪ Cash burn nicely reduced by the steadily increasing revenues, break - even in the not - too

Slide 8: Reverse Merger Announced
8 Reverse Merger Announced ▪ The surviving company will change its name to Emmaus Life Sciences ▪ Nasdaq - listed – MYnd [MYND] will spin off legacy business, assets and liabilities to its shareholders ▪ Emmaus’ ownership ratio of the combined entity will be approximately 94% ▪ Closing expected in Q

Slide 9: Sickle Cell Disease
9 Sickle Cell Disease 9 Low life expectancy – and those that do reach adult age suffer terrible lives – excruciating pain, frequent hospitalizations, in the grip of a disease that affects family, relationships and work □ An inherited disease – autosomal recessive disorder -- each parent carries one

Slide 10: Market for Treatment of Sickle Cell Disease
10 Market for Treatment of Sickle Cell Disease □ A Worldwide Issue ▪ Orphan Disease – U.S. (100,000) and Europe (80,000) ▪ Middle East, North Africa (MENA) region 500,000 patients ▪ High prevalence in Brazil, Rest of South America and Africa ▪ 20 to 25 million patients worldwide □ Unmet Medical Need

Slide 11: Positioning our product Endari
11 Positioning our product Endari™ 11 Hospitalization Pain meds (opioids) Hydroxyurea Before… Endari™ ▪ Highly efficacious ▪ Well - tolerated ▪ Clean side - effect profile ▪ Orally administered ▪ Moderately priced Selectin inhibitors GBT’s Hb O₂ binding enhancer blu ebird’s Lenti - Globin Future… En

Slide 12: Endari (L-Glutamine) mechanism of action
12 Endari (L - Glutamine) mechanism of action 12 Oxidants such as O₃, H₂O₂ and O₂ ● are present in all cells, but to an even greater extent in the red cells of sickle cell patients These oxidants drive a reduction in the redox ratio and tilt the NAD⁺ and NADH equilibrium toward NAD⁺ (oxidized form)

Slide 13: Endari – it works
13 13 Endari – it works

Slide 14: Phase 3 Clinical Trial
14 Phase 3 Clinical Trial 14 □ Multicenter, randomized, placebo - controlled, double blind □ Total of 230 patients (ages 5 to 58 years; 53.9% female), assigned 2:1 to treatment arm 152 treatment arm; 78 placebo □ Treatment period 48 weeks □ Concomitant hydroxyurea use – 66% of patients □ Endpoints P

Slide 15: Phase 3 Results
15 Phase 3 Results 15 Results (1) Primary Endpoint Secondary Endpoint Additional Analysis Difference between treated and placebo arms Lower frequency of sickle cell crises Lower frequency of hospitalization Lower cumulative hospital days Delay in the onset of first sickle cell crises Lower incidence

Slide 16: Endari Commercialization – Addressable Market
16 Endari Commercialization – Addressable Market □ U.S. ▪ Highly concentrated market – allows for efficient distribution ▪ Converting 20% of the 100,000 patient market translates to $400 million (average annual ASP of $20,000) □ EU ▪ Europe – distributor ▪ Converting 20% of the 80,000 patient market

Slide 17: Endari Commercialization – Sales Network
17 Endari Commercialization – Sales Network 17 □ Sales force hired through Publicis, a Contract Sales Organization ▪ Targeting SCD hematologists, physicians and sickle cell treatment centers □ Big 3 distributors – AmerisourceBergen, Cardinal, McKesson ▪ Pharmacy network approximately 150 pharmacies

Slide 18: Competitors – other approaches
18 Competitors – other approaches □ Marketed Product ▪ Hydroxyurea □ Developmental Products ▪ Global Blood Therapeutics – small molecule that modifies hemoglobin – oxygenated state – introducing a new efficacy measure – Hb improvement > 1g/dL vs. baseline – seeking accelerated approval ▪ Novartis AG

Slide 19: Emmaus Patent Landscape
19 Emmaus Patent Landscape 19 Diverticulosis (IND approved) • Patents approved: U.S., EU, Australia, China, Russia, Japan, South Korea, Mexico and Indonesia • Patents pending: Brazil and India Diabetes • Patents approved: Japan and EU • Patents pending: U.S., China, Brazil, India, Philippines, and I

Slide 20: A biopharmaceutical company with a plan for sustainable growth
20 We are a biopharmaceutical company with a plan for sustainable growth Initial thrust in sickle cell disease (SCD) Series of product platforms provides for growth across decades 20 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 SCD OUS Markets Diverticulosis SCD US Market

Slide 21: Contact: Kurt Kruger, CFO
21 21 Contact : Kurt Kruger, CFO kkruger@emmauslifesciences . com
Source: SEC EDGAR · 425 filed Jan 7, 2019
More decks from Emmaus Life Sciences, Inc.
Investor Presentation (August 2026)27 slides · August 2026
Investor Presentation (April 2022)31 slides · April 2022
Investor Presentation (November 2021)30 slides · November 2021
Shareholder Meeting (October 2020)18 slides · Oct 29, 2020
Investor Presentation (June 2019)25 slides · Jun 20, 2019
Merger or Acquisition (March 2019)21 slides · Mar 5, 2019